A Randomized Phase II Trial to Assess the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
PET-BOOST
NCT02788461
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
Phase II |
Marianna Perna
514-934-1934 poste 43191
|
A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies
B9991023
NCT03317496
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Phase I |
Olivier Bouchereau
514-934-1934 poste 43129
|
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Brigatinib-2002
NCT03535740
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nicola Raby
514-934-1934 poste 34095
|
Neoadjuvant Platform Trial in Patients With Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
IND.242
NCT05714891
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nicola Raby
514-934-1934 poste 34095
|
A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
KontRASt-02
NCT05132075
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nicola Raby
514-934-1934 poste 34095
Sarah Boujan
514-934-1934 poste 34907
|
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ?50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations
TROPION-Lung08
NCT05215340
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nicola Raby
514-934-1934 poste 34095
|
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
TRUST-II
NCT04919811
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nicola Raby
514-934-1934 poste 34095
|
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
AVANZAR
NCT05687266
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nicola Raby
514-934-1934 poste 34095
|
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
MARIPOSA
NCT04487080
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Corneille Bashagaluke
514-934-1934 poste 34907
|
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy
CANOPY 2
NCT03626545
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Corneille Bashagaluke
514-934-1934 poste 34907
|
Groupe d'étude en oncologie du Québec